This substudy is being conducted in New Zealand.
Lead Investigators:
Dr. Max Bloomfield - Te Whatu Ora - Capital, Coast and Hutt Valley, Wellington Hospital (Maxim.Bloomfield@ccdhb.org.nz)
Dr. Genevieve Walls - Te Whatu Ora - Counties Manukau, Middlemore Hospital (Genevieve.Walls@middlemore.co.nz)
Risks:
SNAP Trial
Daptomycin vs. Vancomycin for the Treatment of MRSA bacteremia
Profiling the genetic and epigenetic determinants that predispose to severe manifestations of Staphylococcus aureus bacteremia
Cell-free DNA is a Versatile Analyte to Monitor Complications and Guide Treatment Duration in Staphylococcus aureus Bacteremia
Derivation and Validation of Phenotypes of Staphylococcus aureus bloodstream infection, with Correlation with Outcome.
PK/PD of oral beta-lactam with and without probenecid for treatment of Staphylococcus aureus bacteraemia.
Significance of S. aureus bacteriuria in patients hospitalized with S. aureus bacteremia